Orville G Kolterman Selected Research

pramlintide (Symlin)

5/2013	Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
5/2007	Is pramlintide a safe and effective adjunct therapy for patients with type 1 diabetes?
4/2005	Properties of pramlintide and insulin upon mixing.
4/2004	Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
1/2004	Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
11/2003	Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
3/2003	Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
1/2003	Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
4/2002	A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
1/2002	Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Orville G Kolterman Research Topics

Disease

6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/2013 - 04/2002
6	Type 2 Diabetes Mellitus (MODY) 01/2005 - 01/2002
4	Nausea 05/2013 - 01/2002
3	Body Weight (Weight, Body) 05/2013 - 01/2002
3	Hypoglycemia (Reactive Hypoglycemia) 03/2003 - 01/2002
2	Weight Loss (Weight Reduction) 04/2004 - 03/2003
1	Overweight 04/2004
1	Weight Gain 04/2002
1	Anorexia 04/2002

Drug/Important Bio-Agent (IBA)

10	pramlintide (Symlin)FDA Link 05/2013 - 01/2002
8	Insulin (Novolin)FDA Link 05/2013 - 01/2002
6	Islet Amyloid PolypeptideIBA 01/2004 - 01/2002
5	Glucose (Dextrose)FDA LinkGeneric 01/2004 - 01/2003
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 05/2013 - 04/2004
2	Exenatide (Byetta)FDA Link 01/2005 - 07/2003
2	Insulin Lispro (Humalog)FDA Link 01/2004 - 11/2003
2	Short-Acting InsulinIBA 01/2004 - 11/2003
2	Hormones (Hormone)IBA 01/2003 - 01/2002
1	Blood Glucose (Blood Sugar)IBA 05/2013
1	Hemoglobins (Hemoglobin)IBA 04/2004
1	Hypoglycemic Agents (Hypoglycemics)IBA 07/2003
1	Metformin (Glucophage)FDA LinkGeneric 03/2003
1	Glucagon (Glukagon)FDA Link 01/2003
1	Triglycerides (Triacylglycerol)IBA 01/2003

Therapy/Procedure

7	Therapeutics 05/2013 - 01/2002
4	Injections 04/2005 - 04/2002
2	Glycemic Control 05/2013 - 04/2002
1	Subcutaneous Injections 03/2003